A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Summary

This trial is comprised of a 4-week randomized, double-blind, placebo-controlled treatment period followed by an optional 8-week open-label extension (OLE) period. This trial will evaluate the efficacy and safety of oral PRAX-114 flexibly dosed at 40 to 60 mg for 4 weeks compared to placebo in adults with PTSD. The OLE period consisting of treatment with 40 mg PRAX-114 for 8 weeks will provide additional efficacy and safety data.

Timeline

Start

2022-01-25

Primary completion

2022-08-01

Completion

2022-09-23

Outcome

Outcome not reported

Stopped: “No longer developing for this indication”

Drugs

Indications